PH12022551177A1 - Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 - Google Patents

Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Info

Publication number
PH12022551177A1
PH12022551177A1 PH1/2022/551177A PH12022551177A PH12022551177A1 PH 12022551177 A1 PH12022551177 A1 PH 12022551177A1 PH 12022551177 A PH12022551177 A PH 12022551177A PH 12022551177 A1 PH12022551177 A1 PH 12022551177A1
Authority
PH
Philippines
Prior art keywords
diseases
compounds
alk5
growth factor
transforming growth
Prior art date
Application number
PH1/2022/551177A
Other languages
English (en)
Inventor
Artal Ramã³N Bosser
Laria Julio Castro Palomino
Casal Begoã±A PampãN
Original Assignee
Agomab Spain S L U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agomab Spain S L U filed Critical Agomab Spain S L U
Publication of PH12022551177A1 publication Critical patent/PH12022551177A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PH1/2022/551177A 2019-11-28 2020-11-27 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 PH12022551177A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19383057 2019-11-28
PCT/EP2020/083566 WO2021105317A1 (en) 2019-11-28 2020-11-27 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Publications (1)

Publication Number Publication Date
PH12022551177A1 true PH12022551177A1 (en) 2024-02-05

Family

ID=68808255

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/551177A PH12022551177A1 (en) 2019-11-28 2020-11-27 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Country Status (16)

Country Link
US (2) US12297186B2 (https=)
EP (1) EP4065572A1 (https=)
JP (2) JP7808032B2 (https=)
KR (1) KR20220107180A (https=)
CN (1) CN114787145B (https=)
AR (1) AR120578A1 (https=)
AU (1) AU2020394531A1 (https=)
BR (1) BR112022010251A2 (https=)
CA (1) CA3160963A1 (https=)
ES (1) ES3029608T1 (https=)
IL (1) IL293388B2 (https=)
MX (1) MX2022005843A (https=)
PH (1) PH12022551177A1 (https=)
SA (1) SA522432749B1 (https=)
WO (1) WO2021105317A1 (https=)
ZA (1) ZA202205149B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3978487A1 (en) 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
TW202543626A (zh) 2024-02-22 2025-11-16 西班牙商亞哥邁伯西班牙有限公司 新穎結晶相形式

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3621540A1 (de) 1986-06-27 1988-01-07 Basf Ag Chinolinderivate, verfahren zu ihrer herstellung, diese enthaltende mikrobizide und ihre verwendung zur bekaempfung von bakterien und pilzen
JP2004521915A (ja) * 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ過剰発現に対するピラゾール誘導体
HRP20050247A2 (en) 2002-09-18 2005-10-31 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2004026302A1 (en) * 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CN102056907B (zh) 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
AR079545A1 (es) 2009-12-21 2012-02-01 Bayer Cropscience Ag Tienilpiri(mi)dinilazol
DK2731949T3 (en) * 2011-07-13 2018-06-14 Tiumbio Co Ltd 2-PYRIDYL-SUBSTITUTED IMIDAZOLS AS ALK5 AND / OR ALK4 INHIBITORS
US11021468B2 (en) * 2015-04-01 2021-06-01 Rigel Pharmaceuticals, Inc. TGF-ß inhibitors
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
JP2021518855A (ja) 2018-03-02 2021-08-05 ユニヴェルシテ ド ローザンヌ Ｗｎｔシグナル伝達経路阻害剤としてのピラゾール誘導体
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
CN110433164A (zh) * 2019-08-15 2019-11-12 南开大学 TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用
EP3978487A1 (en) 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Also Published As

Publication number Publication date
IL293388B1 (en) 2025-12-01
ES3029608T1 (en) 2025-06-24
JP2023504795A (ja) 2023-02-07
AR120578A1 (es) 2022-02-23
IL293388A (en) 2022-07-01
WO2021105317A1 (en) 2021-06-03
CA3160963A1 (en) 2021-06-03
IL293388B2 (en) 2026-04-01
EP4065572A1 (en) 2022-10-05
US20230025933A1 (en) 2023-01-26
US12297186B2 (en) 2025-05-13
ZA202205149B (en) 2025-06-25
JP7808032B2 (ja) 2026-01-28
CN114787145A (zh) 2022-07-22
BR112022010251A2 (pt) 2022-09-06
SA522432749B1 (ar) 2025-05-12
KR20220107180A (ko) 2022-08-02
MX2022005843A (es) 2022-07-19
JP2025163046A (ja) 2025-10-28
AU2020394531A1 (en) 2022-06-09
US20250333395A1 (en) 2025-10-30
CN114787145B (zh) 2024-03-26

Similar Documents

Publication Publication Date Title
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
CR20230310A (es) Inhibidores de prmt5
PH12021550674A1 (en) Protein tyrosine phosphatase inhibitors
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
GEAP202515818A (en) Amino quinazoline derivatives as p2x3 inhibitors
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
MX2023000521A (es) Derivados de piridazinil-amino como inhibidores de el receptor tipo i de factor de crecimiento transformante beta (alk5).
PH12021552375A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
NZ762437A (en) Novel heterocyclic compounds as cdk8/19 inhibitors
ZA202107777B (en) Voruciclib polymorphs and methods of making and using thereof
MX2022004878A (es) Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.
PH12022552727A1 (en) COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE
ZA202205149B (en) Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
MX2024008558A (es) Derivados de piridazinil amino como inhibidores del receptor del factor de crecimiento transformante b de tipo i (alk5).
PH12022500015A1 (en) Ccr6 receptor modulators
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
MX2025001865A (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
SA521421098B1 (ar) -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين
EP4620940A3 (en) Synthesis of (+)-cannabinoids and their therapeutic effects
PH12018502280A1 (en) Tetrahydropyran and thiopyran derivatives having multimodal activity against pain
MX2024003930A (es) Moduladores de trpml, sus composiciones y metodos de uso.